These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9750511)

  • 1. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer].
    Takeuchi S; Saitoh H
    Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
    Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
    J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
    Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
    J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study.
    Samma S; Kagebayashi Y; Yasukawa M; Fukui Y; Ozono S; Hirao Y; Sato H; Okajima E
    Jpn J Clin Oncol; 1997 Feb; 27(1):26-30. PubMed ID: 9070337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastases].
    Takeuchi S; Yoshida K
    Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1521-7. PubMed ID: 7990300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ
    J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
    Noguchi M; Noda S
    J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients.
    Hou MF; Lin SB; Yuan SS; Tsai LY; Tsai SM; Hsieh JS; Huang TJ
    Ann Clin Lab Sci; 2003; 33(1):55-61. PubMed ID: 12661898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone metabolism and phosphorus metabolism in patients with prostate cancer: paracrine and endocrine effects produced by prostate neoplasm].
    Satani H; Yamakawa K; Kawamura J; Mori O; Saito K; Kato H; Tochigi H; Sakurai M; Kato T
    Hinyokika Kiyo; 1997 Dec; 43(12):849-54. PubMed ID: 9488931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The biochemical markers of bone remodeling in cancer patients with skeletal involvement].
    Liubimova NV; Bronnikov IIu; Robins SP; Trapeznikova MF; Kushlinskiĭ NE
    Vopr Onkol; 2000; 46(3):290-7. PubMed ID: 10976274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases.
    Walls J; Assiri A; Howell A; Rogers E; Ratcliffe WA; Eastell R; Bundred NJ
    Br J Cancer; 1999 Jun; 80(8):1265-70. PubMed ID: 10376982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
    Massidda B; Ionta MT; Foddi MR; Mascia L; Bruder F; Aloi MB; Meleddu C; Giannoni MN
    Anticancer Res; 1996; 16(4B):2221-3. PubMed ID: 8694547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of bone turnover in prostate cancer.
    Garnero P
    Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
    Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
    J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
    Lorente JA; Morote J; Raventos C; Encabo G; Valenzuela H
    J Urol; 1996 Apr; 155(4):1348-51. PubMed ID: 8632571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum osteoprotegerin as a novel marker of bone metastasis in prostate cancer].
    Chen HX; Li HZ; Li HJ; Shi BB; Jin W; Cheng XQ
    Zhonghua Wai Ke Za Zhi; 2007 Mar; 45(6):412-4. PubMed ID: 17537330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
    Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
    Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.